Thermo Fisher Scientific Inc. (NYSE:TMO ) TD Cowen 45th Annual Health Care Conference Call March 3, 2025 9:10 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Great. Well, welcome to the 45th Annual TD Cowen Healthcare Conference.
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.
Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.
In the fourth quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 Fourth Quarter Conference call. My name is Ezra, and I will be your coordinator today.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.10 per share, beating the Zacks Consensus Estimate of $5.93 per share. This compares to earnings of $5.67 per share a year ago.
Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue, helped by improved demand for its products and services used in developing therapies.
TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's fourth-quarter 2024 performance.